+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype



Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype



Clinical Pharmacology and Therapeutics 71(1): 89-98



Losartan is metabolized by polymorphic CYP2C9 to E-3174. Our aim was to evaluate the pharmacokinetics of losartan and E-3174 in relation to the CYP2C9 genotype. A 50-mg oral dose of losartan was given to 22 Swedish volunteers with different CYP2C9 genotypes. Losartan and E-3174 were analyzed by HPLC in plasma and urine samples collected up to 24 hours after drug intake. Furthermore, losartan and E-3174 were analyzed in 8-hour urine samples collected from 17 Spanish subjects after a single oral dose of 25 mg losartan. The maximum plasma concentration of E-3174 was significantly (P <.05) lower in the CYP2C9*1/*3 (n = 5) and CYP2C9*2/*3 (n = 4) groups compared with the CYP2C9*1/*1 (n = 6) and CYP2C9*1/*2 (n = 3) groups and extremely low in 1 subject with the CYP2C9*3/*3 genotype. The ratio of the total losartan area under the plasma concentration-time curve (AUC) to the total E-3174 AUC (AUC(losartan)/AUC(E-3174)) was higher in the subject with the CYP2C9*3/*3 genotype (30-fold) and also in the CYP2C9*1/*3 and *2/*3 groups (approximately 2- and 3-fold, respectively) compared with the CYP2C9*1/*1 group. The plasma ratios correlated significantly with the 0- to 8-hour urinary losartan/E-3174 ratios. Among the total of 39 subjects, the urinary ratio was significantly higher in subjects with the CYP2C9*1/*3 (n = 10) and *2/*3 (n = 4) genotypes than in those with the CYP2C9*1/*1 genotype (n = 11; P <.01) and approximately 40-fold higher in subjects with the CYP2C9*3/*3 genotype (n = 3). The CYP2C9*3 allele was shown to be associated with decreased formation of E-3174 from losartan. The significant differences between genotypes in plasma and urine losartan/E-3174 ratios and the good correlation between the plasma and urine ratios suggest that the losartan/E-3174 ratio in 0- to 8-hour urine specimens may serve as a phenotyping assay for CYP2C9 activity. Further studies in larger populations will be required to establish this.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011137730

Download citation: RISBibTeXText

PMID: 11823761

DOI: 10.1067/mcp.2002.121216


Related references

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. International Journal of Clinical Pharmacology and Therapeutics 50(9): 683-689, 2013

Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves. Kardiologiia 53(12): 21-24, 2014

Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Die Pharmazie 68(11): 882-888, 2014

Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. European Journal of Clinical Pharmacology 65(6): 585-591, 2009

Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China. Journal of Clinical Pharmacy and Therapeutics 37(2): 226-231, 2012

The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects. Journal of Clinical Pharmacology 46(3): 310-320, 2006

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88(1-2): 1-9, 2012

Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. Journal of Pharmacy and Pharmacology 62(7): 908-914, 2011

A convenient synthesis by microwave irradiation of an active metabolite (EXP-3174) of losartan. Tetrahedron Letters 44(6): 1149-1152, 2003

Losartan and E-3174 pharmacokinetics in hypertensive children and infants. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 149A, September, 2002

The kinetics of losartan and its active metabolite EXP 3174 in rats Intestinal vs hepatic processes. Pharmazie 53(3 SUPPL 1): 13, March, 1998

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clinical Pharmacology and Therapeutics 59(3): 268-274, 1996

The metabolism of losartan to the active metabolite E-3174 in subjects who are extensive and poor metabolizers of debrisoquine or mephenytoin. British Journal of Clinical Pharmacology 43(2): 215, 1997

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clinical Pharmacology and Therapeutics 65(3): 348-352, 1999

Characterisation of central and peripheral tissue distribution of the angiotensin II antagonist losartan and its active metabolite EXP 3174 in the rat. European Journal of Pharmaceutical Sciences 2(1-2): 161, 1994